Propofol (DB00818): A Comprehensive Clinical and Pharmacological Monograph

Introduction

Propofol, chemically identified as 2,6-diisopropylphenol, is a short-acting, intravenously administered hypnotic agent that has become a cornerstone of modern anesthetic practice.[1] Since its widespread introduction, it has fundamentally reshaped the landscape of anesthesia, primarily due to a highly favorable pharmacokinetic profile characterized by rapid and smooth induction of anesthesia, predictable dose-dependent effects, and a clear-headed, swift recovery.[3] These properties have been instrumental in facilitating the global expansion of ambulatory (day-case) surgery and have established propofol as the principal agent for total intravenous anesthesia (TIVA) techniques.[4] Its utility extends beyond the operating room to procedural sedation and the sedation of critically ill patients in the intensive care unit (ICU).[3]

This clinical versatility, however, is balanced by a significant and demanding risk profile. Propofol possesses a narrow therapeutic window, meaning the dose required for sedation is close to that which can cause profound, life-threatening cardiorespiratory depression, including hypotension, apnea, and loss of protective airway reflexes.[9] This inherent risk is compounded by the lack of a specific pharmacological reversal agent, mandating its administration by personnel expertly trained in general anesthesia and advanced airway management.[12] Furthermore, its lipid emulsion formulation creates a potential vector for microbial contamination if strict aseptic technique is not followed.[3] The drug also carries a potential for abuse, particularly among healthcare professionals, and is associated with the rare but often lethal complication of Propofol Infusion Syndrome (PRIS) when used at high doses or for prolonged periods.[12]

This monograph provides an exhaustive, expert-level analysis of propofol, integrating decades of research and clinical experience. It will synthesize data on its history, physicochemical properties, core pharmacology, diverse clinical applications, and comprehensive safety profile. By examining the intricate connections between its molecular structure, physiological effects, and clinical realities, this report aims to equip the clinician and researcher with the nuanced and in-depth understanding required for the safe and effective use of this transformative medication.

Section 1: Historical Development and Discovery

1.1 The Pre-Propofol Era: The Need for a Better IV Anesthetic

The history of modern anesthesia began in the mid-19th century with the public demonstration of inhaled agents like diethyl ether and chloroform, which for the first time made painless surgery possible.[7] While inhaled anesthetics remained the standard for maintaining unconsciousness, the introduction of intravenous (IV) agents offered a more rapid and pleasant induction. In 1934, sodium thiopental (Pentothal), a barbiturate, was introduced and quickly became the undisputed "gold standard" for IV induction of anesthesia.[16] Its appeal lay in its ability to produce a rapid and smooth loss of consciousness without the excitatory side effects common to some other agents.[18]

However, thiopentone possessed a critical limitation that constrained its use. It is metabolized relatively slowly, and its high lipophilicity causes it to redistribute from the brain to other body tissues, particularly fat, where it accumulates. Consequently, repeated injections or a continuous infusion to maintain anesthesia resulted in a significantly prolonged and unpredictable recovery, often accompanied by a "hangover" effect.[7] This pharmacokinetic profile made thiopentone suitable for induction as a single bolus but largely impractical for maintaining anesthesia during a procedure. This limitation created a distinct clinical need for an ideal IV anesthetic: a drug that combined the rapid, smooth onset of thiopentone with a rapid metabolic clearance that would allow for both induction and maintenance of anesthesia with a quick, clear-headed recovery, free from accumulation.[7]

1.2 The ICI Project: The Birth of Propofol

In 1972, the pharmaceuticals division of Imperial Chemical Industries (ICI) in the United Kingdom, which had previously found success with the inhalational anesthetic halothane, initiated a project to discover such an ideal IV anesthetic.[7] A key member of this research team was Dr. John B. (Iain) Glen, a veterinarian with a background in clinical anesthesia research who recognized the profound need for a better agent.[1]

The initial search was broad, but a breakthrough came in May 1973 when hypnotic activity was detected in 2,6-diethylphenol, one of a series of alkyl-substituted phenols being screened.[7] Although this specific compound had a slow onset of action, it provided a crucial chemical lead. The team then focused on related structures, and Dr. Glen selected propofol (2,6-diisopropylphenol), a compound that had been synthesized years earlier by ICI chemists as a potential antibacterial agent, for further investigation.[7] Designated with the code name ICI 35868, propofol demonstrated an optimal balance of high hypnotic potency and a more favorable cardiorespiratory profile in animal models compared to other candidates.[1] Crucially, animal studies confirmed its key advantage over thiopentone: recovery was rapid and was not prolonged even after repeated injections, indicating a lack of significant accumulation.[7]

1.3 The Formulation Challenge: A 13-Year Hurdle

The journey from a promising molecule to a viable clinical drug is often determined not by pharmacology alone, but by the science of drug delivery. This was profoundly true for propofol. The active molecule, 2,6-diisopropylphenol, is an oil at room temperature and is practically insoluble in water, a fundamental obstacle for an intravenous medication that must be compatible with blood.[7] This formulation challenge would delay its market introduction by 13 years and nearly led to the project's termination.

The first attempt to create a usable formulation for human trials in 1977 involved dissolving propofol in Cremophor EL, a polyethoxylated castor oil surfactant that could create an aqueous solution.[7] While this allowed for initial clinical studies, the Cremophor EL vehicle itself was problematic. By 1980, after over 1000 patients had been studied, an unacceptably high incidence of anaphylactoid reactions was observed, forcing a halt to all clinical trials.[7] This setback demonstrated a critical principle: the delivery vehicle can be as important to safety and efficacy as the drug itself. The project was only salvaged by concurrent technological advances in a separate field—emulsion manufacturing. In 1981, the team was able to reopen work on developing a lipid emulsion formulation, a path that had previously failed due to an inability to create sufficiently small and stable lipid particles.[7]

1.4 The "Milk of Amnesia": Success and Global Adoption

The renewed effort in formulation science proved successful. Researchers developed a stable and well-tolerated 1% oil-in-water emulsion using soybean oil as the lipid phase and purified egg lecithin as the emulsifying agent.[7] This formulation, with its distinctive milky white appearance, earned propofol its enduring colloquial name, the "milk of amnesia".[3]

Clinical trials with the new emulsion formulation began in 1983 and confirmed the efficacy and safety profile that had been predicted from the early animal studies, but without the anaphylactoid reactions associated with Cremophor EL.[7] This success paved the way for regulatory approval. Propofol was first approved for clinical use in the United Kingdom in 1986, a full 13 years after its initial discovery.[7] Approval in the United States under the brand name Diprivan followed in October 1989.[7]

The adoption of propofol was further accelerated by the development of sophisticated infusion pumps, such as the Diprifusor Target-Controlled Infusion (TCI) system, which incorporated pharmacokinetic models to help clinicians maintain a steady level of anesthesia, further solidifying its role in the maintenance of anesthesia.[7] Propofol's rapid, clear-headed recovery and its beneficial anti-emetic properties quickly made it the IV induction agent of choice worldwide, largely replacing thiopentone and transforming anesthetic practice.

Section 2: Physicochemical Properties and Formulation

The clinical behavior of propofol is a direct consequence of its fundamental chemical and physical characteristics. Its identity as a lipophilic alkylphenol dictates not only its mechanism of action but also the very formulation required for its administration and its complex pharmacokinetic profile.

2.1 Chemical Identity and Structure

Propofol is a small molecule classified as a substituted alkylphenol.[22] Its precise chemical name is 2,6-diisopropylphenol, also written as 2,6-bis(1-methylethyl)phenol.[9] The structure consists of a simple phenol ring with two isopropyl groups attached at positions 2 and 6. Its molecular formula is

C12​H18​O, and it has a molecular weight of approximately 178.27 g/mol.[12] The drug is identified across scientific and regulatory databases by a consistent set of identifiers, most notably the CAS (Chemical Abstracts Service) Number 2078-54-8 and the DrugBank ID DB00818.[9]

2.2 Physicochemical Characteristics

Propofol's high lipophilicity is its single most important physicochemical property, from which its rapid onset, formulation requirements, and multi-compartment distribution kinetics all derive. At room temperature, pure propofol is a light-straw-colored, viscous oil or liquid that solidifies into a crystalline solid at its melting point of 18°C.[21]

Its high lipophilicity is quantitatively demonstrated by its very poor solubility in water (approximately 124 mg/L) and its high octanol/water partition coefficient (LogP) of approximately 3.8, with a partition ratio of 6761:1.[2] This means it is thousands of times more soluble in lipids than in water. Chemically, propofol is a weak organic acid with a

pKa of 11.[14] At the physiological pH of blood (~7.4), which is well below its

pKa, the molecule exists almost entirely in its non-ionized, lipid-soluble form. This non-ionized state allows for extremely rapid diffusion across the lipid-rich membranes of the blood-brain barrier, which is the basis for its remarkably fast onset of action.[12]

2.3 Formulation: The Lipid Emulsion

The very lipophilicity that grants propofol its rapid access to the brain also makes it impossible to administer as a simple aqueous solution. This necessitated its development as a formulation that could be safely administered intravenously. The result is the iconic white, oil-in-water emulsion that is synonymous with the drug.[3]

The standard 1% formulation is a sterile, nonpyrogenic emulsion containing 10 mg of propofol per mL.[14] The key components of this emulsion are:

• Active Ingredient: Propofol (10 mg/mL)
• Lipid Vehicle: Soybean oil (100 mg/mL), which serves as the oil phase in which the lipophilic propofol is dissolved.[3]
• Emulsifying Agent: Purified egg lecithin (12 mg/mL), a phospholipid that stabilizes the oil droplets within the aqueous phase, preventing them from coalescing.[3]
• Tonicity Agent: Glycerol (22.5 mg/mL), which is added to make the emulsion isotonic with blood, minimizing osmotic stress on red blood cells during injection.[3]
• pH Adjustment: Sodium hydroxide is used to adjust the final pH to a range of 7 to 8.5.[14]

A critical consideration for this formulation is its potential to support microbial growth, a risk stemming from the lipid and nutrient content of the emulsion.[3] This risk makes strict aseptic technique during handling an absolute requirement.[14] To mitigate this danger, manufacturers add antimicrobial retardants to the formulation. The original Diprivan formulation and many generics contain 0.005% disodium edetate (EDTA), a chelating agent that inhibits bacterial growth.[3] Some generic formulations may instead contain sodium metabisulfite, which can be a concern for patients with sulfite sensitivity or asthma.[32] The entire product is packaged under nitrogen gas to prevent oxidative degradation of the propofol molecule.[21] Any sign of emulsion instability, such as excessive creaming, aggregation of droplets, or phase separation, indicates the product is compromised and must be discarded.[35]

The formulation itself is not without clinical consequences. The lipid load can contribute to hypertriglyceridemia, especially during prolonged infusions, and the presence of egg and soy components forms the basis for labeled contraindications in allergic patients.[34] This illustrates the inseparable link between a drug's active molecule and its delivery vehicle; the emulsion solves the problem of solubility but introduces its own set of clinical considerations and risks.

Table 2.1: Propofol Identifiers and Physicochemical Properties

Identifier/Property	Value	Source Snippets
IUPAC Name	2,6-di(propan-2-yl)phenol	9
CAS Number	2078-54-8	9
DrugBank ID	DB00818	9
Molecular Formula	C12​H18​O	12
Molecular Weight	~178.27 g/mol	12
Physical State	Light-straw-colored oil/liquid (>18°C)	21
Melting Point	18 °C	21
Boiling Point	~256 °C	21
pKa	11	14
LogP	~3.8	21
Water Solubility	Very slightly soluble (~124 mg/L)	14

This table provides a high-density, easily scannable summary of the fundamental chemical and physical data that underpin all of propofol's pharmacological and formulation characteristics. It serves as a foundational reference for the subsequent sections. This data directly explains why propofol acts the way it does: its high LogP and pKa explain its rapid CNS entry and need for an emulsion; its molecular weight is crucial for dose calculations and pharmacokinetic modeling. The table thus acts as a logical anchor for the entire report.

Section 3: Core Pharmacology

The clinical utility of propofol is defined by its pharmacodynamic effects on the body and its pharmacokinetic handling by the body. Its mechanism of action produces a reliable state of hypnosis, while its unique time course of action allows for precise control over the depth and duration of anesthesia.

3.1 Pharmacodynamics: How Propofol Affects the Body

Primary Mechanism of Action: GABA-A Receptor Modulation

Propofol exerts its primary hypnotic effect by acting as a positive allosteric modulator of the γ-aminobutyric acid type A (GABAA​) receptor, which is the most important inhibitory neurotransmitter receptor in the central nervous system (CNS).[2] Propofol binds to a distinct site on the receptor, primarily on its β-subunit, which is different from the binding sites for GABA, benzodiazepines, and barbiturates.[22] This binding does not activate the receptor on its own at low concentrations but rather enhances the effect of the endogenous neurotransmitter, GABA. It potentiates the receptor's function by decreasing the rate at which GABA dissociates from its binding site.[3] This action prolongs the duration of the opening of the receptor's associated chloride ion channel, leading to an increased influx of chloride ions into the neuron. The resulting hyperpolarization of the postsynaptic membrane makes the neuron less likely to fire an action potential, causing widespread CNS depression and hypnosis.[22] At the higher concentrations achieved during clinical anesthesia, propofol can also directly activate the

GABAA​ receptor, even in the absence of GABA, contributing to its profound anesthetic effect.[32]

While its action on GABAA​ receptors is primary, propofol also has secondary mechanisms that may contribute to its overall profile, including inhibition of the N-methyl-D-aspartate (NMDA) receptor, modulation of calcium influx through slow calcium ion channels, and inhibition of voltage-gated sodium channels.[26]

Systemic Effects (Dose-Dependent)

Propofol's effects extend beyond the CNS, impacting multiple organ systems in a dose-dependent manner.

Central Nervous System (CNS): Propofol induces a continuum of CNS depression, from light sedation to deep general anesthesia, with a corresponding decrease in the level of consciousness.[3] This is accompanied by a beneficial reduction in the cerebral metabolic rate for oxygen (

CMRO2​), cerebral blood flow (CBF), and intracranial pressure (ICP), making it a favored agent in neuroanesthesia and for patients with brain injury.[3] It possesses potent anticonvulsant properties and is used off-label to treat refractory status epilepticus.[3] Paradoxically, it can also cause excitatory phenomena such as myoclonic movements or twitching, particularly during induction.[3] Another valuable CNS effect is its antiemetic action, which reduces the incidence of postoperative nausea and vomiting (PONV), likely through a direct depressant effect on the chemoreceptor trigger zone in the brainstem.[3] Animal studies also suggest potential neuroprotective effects through the reduction of oxidative damage.[3]

Cardiovascular System: Propofol has more pronounced hemodynamic effects than many other intravenous anesthetics.[9] It causes significant hypotension, which is often the most immediate clinical concern upon administration. This drop in blood pressure, which can be greater than 30%, is primarily due to potent arterial and venous vasodilation, resulting from the inhibition of sympathetic nervous system activity.[2] This is coupled with a mild negative inotropic (myocardial depressant) effect.[3] The hemodynamic impact is particularly pronounced after a rapid bolus injection and in patients who are elderly, hypovolemic, or have pre-existing cardiac dysfunction.[3] Unlike some anesthetics, propofol has no vagolytic activity to counteract vagal tone, and thus bradycardia, and in rare cases asystole, can occur, especially when co-administered with other vagotonic drugs or in response to surgical stimuli.[33]

Respiratory System: Propofol is a powerful, dose-dependent respiratory depressant.[3] It acts centrally to inhibit the hypercapnic ventilatory drive, blunting the body's response to rising carbon dioxide levels.[3] An induction dose of propofol reliably and frequently produces a period of apnea, which can persist for more than 60 seconds.[9] This respiratory depression is significantly potentiated by the concurrent use of other CNS depressants, particularly opioids and benzodiazepines.[3] While it can depress respiration, propofol also has bronchodilator properties, which can be advantageous in patients with asthma or reactive airway disease.[32]

3.2 Pharmacokinetics: How the Body Processes Propofol

The pharmacokinetic profile of propofol is central to its clinical utility, defining its rapid onset and its context-dependent duration of action.

Administration and Onset: Propofol is administered exclusively by the intravenous route. Following a bolus injection, it produces unconsciousness with remarkable speed and reliability, typically within 15 to 40 seconds.[9] This rapid onset is due to its high lipophilicity, which allows it to quickly cross the blood-brain barrier and achieve effective concentrations in the CNS within a single arm-brain circulation time.[14]

Distribution: Once in the bloodstream, propofol is highly protein-bound (95-99%), primarily to albumin and hemoglobin.[3] Its pharmacokinetics are best described by a three-compartment model, reflecting its extensive distribution throughout the body.[40] These compartments consist of:

1. The central compartment (plasma and vessel-rich organs).
2. A rapidly equilibrating peripheral compartment (well-perfused tissues, including the brain and muscle).
3. A slowly equilibrating peripheral compartment (poorly perfused tissues, primarily adipose tissue). The drug's high lipophilicity results in a very large volume of distribution, which can approach 60 L/kg after a prolonged infusion, indicating significant sequestration in body tissues.3

Metabolism: Propofol is cleared from the body rapidly and extensively. The clearance rate (23-50 mL/kg/min) is so high that it exceeds total hepatic blood flow, which is definitive evidence of significant extrahepatic metabolism.[3] Approximately 60% of this clearance occurs in the liver, where the molecule undergoes phase II conjugation to form inactive propofol glucuronide and sulfate metabolites.[3] The remaining 40% of clearance occurs at extrahepatic sites, with the kidneys being a primary contributor.[3] All metabolites are pharmacologically inactive and are excreted in the urine.[3] A rare but benign side effect is green discoloration of the urine, which is attributed to the renal excretion of phenolic metabolites.[3]

Elimination and Half-Life: The termination of propofol's clinical effect is highly dependent on the duration of its administration. This creates a paradox where the drug's ease of use in short procedures can mask its complexity in long-term sedation.

• Termination of Action (Single Bolus): After a single induction dose, a patient awakens quickly, typically within 5 to 10 minutes.[9] This rapid recovery is not due to metabolism but is instead caused by the rapid redistribution of the drug from the brain (the effect site) into other less-perfused tissues like muscle and fat.[3]
• Pharmacokinetic Half-Lives: The decline in plasma concentration is multiphasic. The initial distribution half-life (t1/2α​) is very short, around 2-4 minutes, reflecting this rapid redistribution phase. The terminal elimination half-life (t1/2β​), which reflects the ultimate clearance of the drug from the body, is much longer, typically in the range of 4-7 hours.[3]
• Context-Sensitive Half-Time: For continuous infusions, the most clinically relevant parameter is the context-sensitive half-time. This value describes the time required for the plasma drug concentration to decrease by 50% after an infusion of a specific duration is stopped. For propofol, this time increases dramatically with the duration of the infusion. This is because, over time, the large, slow peripheral compartment (adipose tissue) becomes saturated with the lipophilic drug.[40] When the infusion is stopped, propofol slowly leaches back out of this fat reservoir into the plasma, significantly prolonging the time to awakening. While the context-sensitive half-time is short after brief infusions, it can extend to 1-3 days after a 10-day infusion.[3] This phenomenon explains why a patient may awaken in minutes after a short anesthetic but can take hours or even days to emerge from sedation after a prolonged ICU course if the infusion is not carefully titrated downwards over time.

Table 3.1: Key Pharmacokinetic Parameters of Propofol

Parameter	Value	Clinical Significance/Notes	Source Snippets
Onset of Action	15–40 seconds	Extremely rapid due to high lipophilicity and rapid brain equilibration.	9
Duration of Action (single bolus)	5–10 minutes	Termination of effect is due to rapid redistribution from CNS to other tissues, not metabolism.	3
Protein Binding	95–99%	Highly bound to albumin and hemoglobin; changes in protein levels could affect free drug concentration.	3
Volume of Distribution (Vd​)	Large (~60 L/kg after long infusion)	Reflects extensive uptake into peripheral tissues, especially fat.	3
Clearance	High (23–50 mL/kg/min)	Exceeds hepatic blood flow, indicating significant extrahepatic (e.g., renal) metabolism.	3
Metabolism	Hepatic (60%) and extrahepatic (40%) conjugation to inactive metabolites.	Rapid and extensive metabolism contributes to its favorable profile for infusions.	3
Terminal Elimination Half-Life	4–7 hours (can be up to 31 hours)	Represents final elimination from the body but is not predictive of awakening after infusion.	3
Context-Sensitive Half-Time	Increases with infusion duration (e.g., up to 1–3 days after a 10-day infusion)	The most critical parameter for predicting recovery after infusions. Explains potential for slow awakening after long-term use.	3

This table crystallizes the complex pharmacokinetic data into a clinically applicable format. It directly contrasts the rapid termination of effect after a bolus with the potential for slow recovery after long infusions, a critical concept for clinicians to grasp. It highlights the distinction between elimination half-life and context-sensitive half-time, which is a common point of confusion but is essential for safe use of propofol in infusions. By placing these values side-by-side, it visually reinforces the drug's dynamic nature and the importance of considering the duration of administration when predicting recovery.

Section 4: Clinical Applications and Administration

Propofol's unique pharmacological profile has secured its role as a versatile and indispensable agent in a wide array of clinical settings, from the operating room to the intensive care unit and procedural suites. Its use is governed by specific approved indications, well-defined dosing guidelines, and stringent protocols for administration and handling that are essential for patient safety.

4.1 Approved and Off-Label Indications

The U.S. Food and Drug Administration (FDA) has approved propofol for several key indications in specific patient populations.[42]

FDA-Approved Indications:

• Induction of General Anesthesia: For initiating a state of general anesthesia in adult patients and pediatric patients aged 3 years and older.[3]
• Maintenance of General Anesthesia: For sustaining anesthesia after induction in adult patients and pediatric patients aged 2 months and older.[3]
• Monitored Anesthesia Care (MAC) Sedation: For providing sedation during diagnostic or surgical procedures in adult patients where general anesthesia is not required. This includes use in combination with regional anesthesia.[3]
• Intensive Care Unit (ICU) Sedation: For the sedation of intubated, mechanically ventilated adult patients.[8]

Limitations of Use and Unapproved Populations:

The FDA explicitly states that propofol is not recommended for certain uses due to a lack of established safety and effectiveness data or due to specific risks. These include the induction of anesthesia in children younger than 3 years, maintenance of anesthesia in infants younger than 2 months, and any MAC sedation in the pediatric population.42 Critically, propofol is

not indicated for ICU sedation in pediatric patients, a restriction stemming from the heightened risk of developing Propofol Infusion Syndrome (PRIS) in this population.[42]

Common Off-Label Uses:

Beyond its approved indications, propofol's properties have led to its use in several off-label applications by clinicians:

• Refractory Status Epilepticus: Its potent anticonvulsant effects make it a valuable agent for controlling seizures that have not responded to standard therapies, in both adults and children.[3]
• Refractory Postoperative Nausea and Vomiting (PONV): Small, sub-anesthetic doses of propofol can be effective in treating PONV that is resistant to conventional antiemetics.[3]
• Delirium Tremens: It is sometimes used for sedation in severe cases of alcohol withdrawal.[32]

4.2 Dosing and Administration Guidelines

Propofol dosing is highly individualized and must be carefully titrated against the patient's clinical response to achieve the desired level of sedation or anesthesia while minimizing adverse hemodynamic effects.[14] Doses are generally reduced for elderly, debilitated, or hemodynamically unstable patients (American Society of Anesthesiologists Physical Status III or IV), and for patients who have received premedication with opioids or other sedatives.[46]

Induction of General Anesthesia:

• Healthy Adults (<55 years, ASA I/II): The typical induction dose is 1.5 to 2.5 mg/kg administered intravenously. This is often given in increments, such as 40 mg every 10 seconds, until the clinical signs of anesthesia appear.[35]
• Elderly, Debilitated, or ASA III/IV Patients: The dose is reduced to 1 to 1.5 mg/kg, and the injection rate is slowed (e.g., 20 mg every 10 seconds) to allow time to assess the effect and mitigate the risk of severe hypotension.[14]
• Pediatric Patients (3-16 years): Children generally require a higher weight-based dose than adults, typically 2.5 to 3.5 mg/kg, with younger children often needing doses at the higher end of this range.[46]

Maintenance of General Anesthesia:

• Adults: Anesthesia can be maintained with a variable-rate infusion, typically starting at 100-200 mcg/kg/min and then reduced to a maintenance rate of 50-100 mcg/kg/min. Alternatively, intermittent IV boluses of 25-50 mg can be given in response to signs of light anesthesia.[46]
• Pediatric Patients (≥2 months): Maintenance is achieved with an infusion of 125-300 mcg/kg/min. Younger children may require higher infusion rates than older children.[46]

Monitored Anesthesia Care (MAC) Sedation (Adults):

• Initiation: Sedation is typically initiated with either a slow infusion of 100-150 mcg/kg/min for 3-5 minutes or a slow injection of 0.5 mg/kg over 3-5 minutes. The slower administration is crucial to avoid overshoot and cardiorespiratory depression.[46]
• Maintenance: A continuous infusion of 25-75 mcg/kg/min is most common, titrated to the desired level of sedation. Small, intermittent boluses of 10-20 mg can also be used.[46]

ICU Sedation (Adults):

• Initiation: Infusions are generally started at a low rate, such as 5 mcg/kg/min (0.3 mg/kg/hr), and titrated upward in small increments (5-10 mcg/kg/min) every 5-10 minutes until the desired sedation level is reached.[46]
• Maintenance: The dose is highly variable depending on patient needs. It is critical to titrate to the minimum effective dose and to re-evaluate sedation levels daily. Infusion rates exceeding 4 mg/kg/hr (approximately 67 mcg/kg/min) for more than 48 hours are strongly associated with an increased risk of PRIS and should be avoided if possible.[15]

4.3 Critical Administration and Handling Protocols

The safe use of propofol is underpinned by strict protocols related to its handling and the environment in which it is administered. These protocols are not merely recommendations but are fundamental safety requirements codified in the drug's labeling and professional society guidelines. The mandate that propofol be administered only by personnel trained in general anesthesia is a direct regulatory and clinical response to its inherent risks. The drug has a narrow therapeutic index and no reversal agent, meaning the line between conscious sedation and a state of general anesthesia with airway compromise is thin and can be crossed unexpectedly.[10] The only way to manage the most severe complications—apnea, airway obstruction, and cardiovascular collapse—is through advanced airway management (e.g., intubation), positive pressure ventilation, and hemodynamic resuscitation with vasopressors.[10] These are the core competencies of an anesthesia provider. Thus, the package insert warning is a foundational safety principle: the primary risk mitigation strategy for propofol is to ensure the person administering it is immediately capable of rescuing the patient from its most dangerous effects.[13]

Key protocols include:

• Administration Personnel: For general anesthesia or MAC sedation, propofol must be administered only by persons trained in the administration of general anesthesia (e.g., anesthesiologists, certified registered nurse anesthetists) who are not simultaneously involved in performing the surgical or diagnostic procedure.[13]
• Aseptic Technique: Because the lipid emulsion formulation can support rapid microbial growth, strict aseptic technique is mandatory at all times. The vial stopper must be disinfected, and the drug drawn into a sterile syringe. Failures in aseptic technique have been linked to outbreaks of fever, infection, sepsis, and death.[3]
• Single-Patient Use: Propofol vials are for single-patient, single-access use only. Administration should begin promptly after opening the vial and must be completed within 12 hours. Any unused drug and all associated IV tubing must be discarded after 12 hours (or at the end of the procedure, whichever comes first) to prevent contamination.[14]
• Patient Monitoring: Continuous, uninterrupted patient monitoring is essential. This must include assessment of level of consciousness, respiratory rate, and oxygen saturation via pulse oximetry. Crucially, monitoring for the presence of exhaled carbon dioxide (capnography) should be utilized, as it provides the most reliable early warning of apnea or airway obstruction. Blood pressure and heart rate must be monitored at regular, frequent intervals.[13]
• Emergency Equipment: A full complement of emergency equipment must be immediately available wherever propofol is administered. This includes equipment for maintaining a patent airway, providing artificial ventilation (e.g., bag-valve-mask, intubation supplies), administering supplemental oxygen, and instituting full cardiovascular resuscitation.[13]

Section 5: Safety Profile and Risk Management

While propofol's efficacy is well-established, its use requires a thorough understanding of its adverse effects, contraindications, drug interactions, and potential for abuse. Managing these risks is central to its safe clinical application.

5.1 Common and Significant Adverse Effects

The adverse effects of propofol are generally dose-dependent and predictable.

• Injection Site Pain: This is the most frequently reported adverse effect, described as a burning or stinging sensation upon injection.[3] The pain is more common when using smaller veins of the hand compared to larger veins of the forearm or antecubital fossa. It is thought to arise from direct irritation by the free aqueous concentration of propofol activating TRPA1 pain receptors on sensory nerves.[2] The incidence and severity can be significantly reduced by administering a small dose of intravenous lidocaine just prior to or mixed with the propofol injection.[3]
• Cardiovascular Effects: Hypotension is a very common and clinically significant side effect, resulting from propofol-induced vasodilation and mild myocardial depression.[3] Bradycardia can also occur due to the drug's lack of vagolytic activity.[36]
• Respiratory Effects: Dose-dependent respiratory depression is an expected pharmacological effect, frequently leading to transient apnea following an induction dose.[3] This effect is potentiated by other CNS depressants.[3]
• Central Nervous System Effects: Involuntary myoclonic movements, such as twitching or jerking, are common during induction and are not typically associated with seizure activity on an EEG.[3] While propofol is an effective anticonvulsant, there is a recognized risk of seizures occurring during the recovery phase, particularly in patients with a history of epilepsy.[33]
• Metabolic Effects: Due to the lipid emulsion vehicle, prolonged or high-dose infusions can lead to hypertriglyceridemia and hyperlipidemia.[2] This requires monitoring of lipid levels during long-term ICU sedation.
• Rare Adverse Effects: A number of other adverse effects have been reported, though they are uncommon to rare. These include pancreatitis (potentially linked to hypertriglyceridemia), green discoloration of the urine (due to phenolic metabolites), priapism, dystonia, and anaphylactic or anaphylactoid reactions.[3]

5.2 Contraindications and Precautions

Specific patient conditions preclude the use of propofol or necessitate extreme caution.

• Absolute Contraindications:
• Propofol is strictly contraindicated in patients with a known hypersensitivity to propofol itself or any of the components of its formulation.[2]
• The drug is also contraindicated in patients with a documented allergy to eggs, egg products, soybeans, or soy products, as the emulsion contains egg lecithin and soybean oil.[8] This contraindication is a subject of some debate in clinical practice, as true anaphylactic reactions are typically to the proteins in these foods, whereas the emulsion contains purified oil and phospholipids. Nevertheless, it remains a formal contraindication in the product labeling.[3]
• Precautions and High-Risk Populations:
• Elderly and Debilitated Patients: These patients exhibit increased sensitivity to propofol's effects and have reduced clearance, leading to higher peak plasma concentrations for a given dose. This predisposes them to more profound hypotension and apnea. Dose reduction and slower administration are essential.[14]
• Cardiovascular and Volume Status: Extreme caution is warranted in patients with severe cardiac disease, hypovolemia, or unstable hemodynamics, as they are less able to compensate for propofol's vasodilatory and myocardial depressant effects.[3]
• Disorders of Lipid Metabolism: Patients with pre-existing pancreatitis or severe hyperlipidemia may be at increased risk for exacerbation due to the lipid load of the emulsion.[44]
• Neurological Conditions: Caution is advised in patients with epilepsy due to the risk of recovery-phase seizures.[44] In patients with elevated intracranial pressure, while propofol can be beneficial, it must be used carefully to avoid cerebral perfusion pressure reduction secondary to systemic hypotension.
• Pediatric Neurotoxicity: A general warning applies to most anesthetic and sedation drugs, including propofol. Published animal studies have shown that prolonged (>3 hours) or repeated exposure to agents that block NMDA receptors or potentiate GABA activity during critical periods of brain development can lead to neuronal apoptosis and long-term cognitive deficits. The clinical significance in humans is unclear, but this potential risk should be considered when planning elective procedures in children under 3 years of age.[33]

5.3 Drug Interactions

Propofol's effects can be significantly altered by concomitant medications, primarily through pharmacodynamic synergism.

Table 5.1: Clinically Significant Drug Interactions with Propofol

Interacting Drug/Class	Type of Interaction	Clinical Effect	Management Recommendation	Source Snippets
Opioids (e.g., fentanyl, morphine, remifentanil)	Pharmacodynamic	Potentiation of hypnotic, sedative, and cardiorespiratory depressant effects (hypotension, apnea).	Reduce induction and maintenance doses of propofol. Monitor for profound respiratory depression and hypotension. Be aware of risk of serious bradycardia with fentanyl in pediatrics.	9
Benzodiazepines (e.g., midazolam, lorazepam)	Pharmacodynamic	Synergistic CNS depression, increased sedation, and potentiation of respiratory depression.	Reduce propofol doses. Titrate carefully to desired level of sedation and monitor for excessive depression.	8
Inhalational Anesthetics (e.g., sevoflurane, desflurane)	Pharmacodynamic	Additive anesthetic, sedative, and cardiorespiratory depressant effects.	Reduce propofol maintenance infusion rate when used as part of a balanced anesthetic technique.	40
Other CNS Depressants (e.g., barbiturates, alpha-2 agonists)	Pharmacodynamic	Increased sedation and risk of cardiorespiratory depression.	Use with caution and reduce propofol dosage accordingly.	3
Valproate	Pharmacokinetic	May increase blood levels of propofol, leading to deeper sedation.	Reduce the dose of propofol when co-administered. Monitor closely for increased sedation or cardiorespiratory depression.	40
Beta-blockers, ACE inhibitors	Pharmacodynamic	Increased risk of hypotension due to synergistic effects on blood pressure.	Use with caution. Be prepared to treat hypotension.	46

Drug interactions are a daily concern for anesthesiologists. This table provides a structured, actionable summary of the most critical interactions, moving beyond a simple list to provide management advice. It synthesizes information from multiple sources into a single, coherent guide. This structure helps clinicians anticipate the type of interaction and proactively adjust their anesthetic plan.

5.4 Abuse, Dependence, and Regulation

Propofol possesses a significant potential for abuse, a risk that is unique among general anesthetics. Upon awakening from propofol-induced sedation, patients often report feelings of well-being, euphoria, and talkativeness.[12] Animal studies have shown that these reinforcing effects are likely mediated by an increase in dopamine concentrations in the nucleus accumbens, a key component of the brain's reward system.[12]

This abuse potential has led to tragic consequences, primarily among healthcare professionals with ready access to the drug, including anesthesiologists, nurse anesthetists, and other medical staff.[12] The abuse pattern is particularly dangerous due to propofol's narrow therapeutic window. Self-administration can easily lead to an overdose, resulting in respiratory arrest, anoxia, and death. The mortality rate among anesthesiology personnel who abuse propofol is alarmingly high, with one survey reporting a rate of 28%.[12]

In recognition of its abuse potential and the associated fatalities, the U.S. Drug Enforcement Administration (DEA) took regulatory action. Propofol, including its salts and isomers, was placed into Schedule IV of the Controlled Substances Act (CSA).[68] This scheduling imposes stricter federal regulations on the manufacturing, distribution, and dispensing of the drug, requiring more rigorous record-keeping and security measures to prevent diversion and abuse.

Section 6: Propofol Infusion Syndrome (PRIS): A Comprehensive Analysis

Propofol Infusion Syndrome (PRIS) is a rare, but devastating and often fatal, iatrogenic complication associated with the administration of propofol. It represents the most severe risk associated with the drug's long-term use and requires a high index of suspicion for diagnosis and immediate intervention. The pathophysiology is best understood not as a simple drug toxicity but as a catastrophic failure of cellular energy metabolism, where propofol's mitochondrial inhibition collides with the high-energy demands and altered substrate utilization characteristic of critical illness.

6.1 Definition and Clinical Presentation

PRIS is defined as a constellation of metabolic derangements and multi-organ failure that occurs in the setting of a propofol infusion.[69] While it is most strongly associated with high-dose (>4 mg/kg/hr or ~67 mcg/kg/min) and/or prolonged (>48 hours) infusions, cases have been reported with lower doses and shorter durations.[9]

The clinical presentation is a rapid and progressive decline characterized by a core set of features:

• Cardiac Dysfunction: This is a hallmark of PRIS and often the terminal event. It manifests as acute, refractory bradycardia that progresses to asystole. Other cardiac signs include a wide range of arrhythmias, cardiogenic shock, and characteristic Brugada-like ECG changes (a coved-type ST-segment elevation in the right precordial leads, V1-V3), which are considered a sign of imminent cardiac collapse.[32]
• Severe Metabolic Acidosis: A high anion gap metabolic acidosis, often with markedly elevated lactate levels, is a consistent and early finding.[32]
• Skeletal Muscle Injury: Rhabdomyolysis occurs, leading to massively elevated creatine kinase (CK) levels and myoglobinuria.[38]
• Renal Failure: Acute kidney injury is common, often precipitated by the rhabdomyolysis and cardiovascular collapse.[38]
• Other Key Signs: Hyperkalemia (resulting from rhabdomyolysis and renal failure), hypertriglyceridemia/lipemia (from the lipid infusion), and hepatomegaly with fatty infiltration are also characteristic features.[15]

6.2 Identified Risk Factors

The development of PRIS appears to be multifactorial, arising from an interaction between the drug and a vulnerable patient state.

• Propofol Dose and Duration: This is the most consistently identified and modifiable risk factor. Infusion rates exceeding 4-5 mg/kg/hr and/or a duration of more than 48 hours significantly increase the risk.[15] The risk is related to the cumulative dose.
• Patient's Clinical State: PRIS almost exclusively occurs in critically ill patients. Specific underlying conditions that increase risk include:
• Severe neurological injury (e.g., traumatic brain injury, status epilepticus).[15]
• Sepsis or severe systemic inflammation (e.g., airway infections).[15]
• Young age, with the syndrome originally described in children.[15]
• Metabolic State: A state of carbohydrate depletion, such as in starvation or malnutrition, is a key predisposing factor. In these states, the body is forced to rely on lipid metabolism for energy, a pathway that propofol disrupts.[15]
• Concomitant Medications: The concurrent administration of high-dose catecholamines (vasopressors) and/or glucocorticoids (steroids) is a major risk factor. These stress hormones promote lipolysis, increasing the load of free fatty acids that the mitochondria cannot process.[9]
• Genetic Predisposition: A subclinical or undiagnosed inborn error of mitochondrial fatty acid oxidation may render a patient exquisitely sensitive to the effects of propofol.[15]

6.3 Pathophysiology: A Cascade of Mitochondrial Failure

The underlying mechanism of PRIS is a profound, propofol-induced disruption of cellular energy production at the mitochondrial level. In the high-demand state of critical illness, where the body's energy needs are immense and it is reliant on fat for fuel, propofol delivers a two-pronged attack on the mitochondria, leading to a catastrophic supply-demand mismatch.

1. Impairment of Fatty Acid Oxidation: During critical illness and stress, catecholamines and corticosteroids trigger massive lipolysis, releasing free fatty acids (FFAs) to be used as the primary energy source for high-demand organs like the heart and skeletal muscle.[78] Propofol inhibits carnitine palmitoyltransferase I (CPT-I), the enzyme that acts as a gatekeeper, transporting these FFAs into the mitochondria where they can be oxidized for energy.[38] By blocking this crucial entry step, propofol prevents the body from using its main available fuel source.
2. Disruption of the Electron Transport Chain (ETC): In addition to blocking fuel entry, propofol directly sabotages the mitochondrial "engine" itself. It has been shown to inhibit multiple complexes within the ETC and uncouple oxidative phosphorylation.[38] This action cripples the cell's ability to generate adenosine triphosphate (ATP), the universal energy currency.

This dual mitochondrial toxicity creates a profound energy deficit in tissues with the highest metabolic rates. The heart and skeletal muscles, starved of ATP, undergo necrosis (myocytolysis). Cardiac muscle death leads to arrhythmias and heart failure, while skeletal muscle death leads to rhabdomyolysis. The body, unable to use aerobic metabolism, shifts to anaerobic glycolysis, producing large amounts of lactic acid and causing severe metabolic acidosis. The widespread cell death releases massive amounts of intracellular potassium (hyperkalemia) and myoglobin, which is toxic to the kidneys, leading to acute renal failure. This cascade of events explains the full clinical spectrum of PRIS.

6.4 Management and Prevention

Given the high mortality of PRIS (reports range from 18% to over 50%), prevention is the most effective strategy.[69]

• Prevention:
• Limit Dose and Duration: Adhere to recommended dosing limits, using the lowest effective infusion rate. Avoid rates >4 mg/kg/hr whenever possible.[69] Critically re-evaluate the need for propofol sedation after 48 hours and consider switching to an alternative sedative agent for long-term needs.[15]
• Ensure Carbohydrate Supply: Provide adequate carbohydrate calories (e.g., via nutrition or dextrose infusions) to minimize the body's reliance on fatty acid metabolism.[15]
• Monitoring and Early Recognition:
• Maintain a high index of suspicion in any patient on a propofol infusion who develops unexplained clinical deterioration.
• Monitor for early warning signs, which may include a new or worsening metabolic acidosis, rising serum lactate, rising CK levels, or the appearance of a Brugada-like pattern on the ECG.[73] Routine monitoring of these parameters in high-risk patients may be warranted.
• Treatment of Established PRIS:
• The first and most critical action is the immediate discontinuation of the propofol infusion.[38]
• Treatment is aggressive and supportive, aimed at managing the multi-organ failure. This includes:
• Hemodynamic Support: Use of vasopressors, inotropes, and potentially cardiac pacing to manage refractory bradycardia and cardiovascular collapse.[15]
• Metabolic Correction: Management of severe acidosis and hyperkalemia.
• Renal Replacement Therapy: Hemofiltration or hemodialysis is often necessary to correct acidosis, clear potassium, and manage acute kidney injury.[38]
• Advanced Support: In cases of refractory cardiorespiratory collapse, extracorporeal membrane oxygenation (ECMO) has been used as a life-saving rescue therapy.[38]

Section 7: The Role of Propofol in Modern Anesthesia and Future Directions

Propofol is more than just an anesthetic; it is an agent that has fundamentally altered the practice of anesthesia and sedation. Its introduction marked a paradigm shift, and ongoing research continues to refine its use and explore new therapeutic possibilities. The trajectory of propofol's development shows a clear evolution from a "blunt instrument" used to induce a general state of unconsciousness to a molecular tool whose specific interactions are being harnessed for precision medicine.

7.1 Transformative Impact on Anesthetic Practice

Propofol's unique combination of rapid onset, titratability, and swift, clear-headed recovery has had a profound impact on several areas of medicine.

• Facilitating Ambulatory Surgery: Perhaps its greatest impact has been on day-case surgery. The predictable and rapid recovery, coupled with a lower incidence of postoperative nausea and vomiting compared to older agents, allows patients to meet discharge criteria and return home sooner and more comfortably. This has been a key enabler of the massive shift of surgical procedures to the outpatient setting.[1]
• Enabling Total Intravenous Anesthesia (TIVA): Propofol is the cornerstone of TIVA, a technique that relies solely on intravenous agents for the induction and maintenance of anesthesia, avoiding volatile gases entirely. Its favorable pharmacokinetics, including rapid clearance and minimal accumulation when titrated correctly, make it the ideal hypnotic for this purpose. TIVA offers several advantages, including a superior recovery profile, reduced PONV, and the ability to provide anesthesia for patients susceptible to malignant hyperthermia.[2]
• Improving the Patient Experience: Patients frequently report a more pleasant emergence from propofol anesthesia, often describing a feeling of well-being without the grogginess or "hangover" associated with other agents.[4] This has improved overall patient satisfaction with the anesthetic experience.
• Expanding Procedural Sedation: The drug's titratability and rapid offset have made it the agent of choice for a vast number of diagnostic and therapeutic procedures performed outside the traditional operating room, such as gastrointestinal endoscopy, bronchoscopy, and cardioversion. This expansion, however, has also brought to the forefront critical issues regarding safe administration, credentialing, and the need for anesthesia professional involvement.[24]

7.2 Challenges and Areas for Improvement

Despite its success, challenges in the use of propofol remain, driving ongoing efforts to improve its safety and efficacy.

• Interpatient Variability: There is significant variability in patient response to propofol based on factors like age, weight, cardiac function, genetic makeup, and concomitant medications. This makes precise dosing difficult and underscores the importance of titrating to effect rather than relying on fixed-dose regimens.[9]
• Monitoring Depth of Anesthesia: While clinical signs are the traditional guide, there is a continued push for more objective monitoring of anesthetic depth, such as processed electroencephalography (EEG). This technology can help clinicians guide TIVA more precisely, reducing the risk of both intraoperative awareness and excessively deep anesthesia, which can be associated with adverse outcomes.[24]
• Formulation and Handling Risks: The inherent risks of the lipid emulsion formulation—namely, the potential for catastrophic microbial contamination and the pain on injection—remain significant operational challenges that demand constant vigilance and strict adherence to protocols.[3]

7.3 Innovations and Future Research Directions

Research into propofol is moving in several exciting directions, focused on creating safer delivery methods, refining the molecule itself, and discovering entirely new therapeutic uses. This evolution represents a shift from general application to precision targeting.

• New Formulations and Prodrugs:
• Fospropofol (Lusedra): To address the issue of injection pain and formulation instability, a water-soluble prodrug, fospropofol, was developed. In the body, the enzyme alkaline phosphatase cleaves the phosphate group, releasing active propofol. While it successfully eliminates injection pain, fospropofol has a slower onset and offset of action, which has limited its widespread adoption.[9]
• Novel Delivery Systems: Advanced pharmaceutical research is exploring novel delivery systems, such as self-nanoemulsifying drug delivery systems (SNEDDS), to improve the bioavailability of propofol and potentially enable non-intravenous routes of administration in the future.[31]
• Safer Derivatives:
• Ciprofol (HSK3486): A new chemical entity and a derivative of propofol, ciprofol is an important step in refining the molecule. It is a stereoisomer that is 4 to 6 times more potent than propofol. Clinical trials suggest it may have a more favorable safety profile, with a lower incidence of injection site pain and respiratory depression, representing an effort to optimize the therapeutic window.[9]
• Emerging Therapeutic Applications:
• Targeted Epilepsy Treatment: Groundbreaking research has identified a specific binding site for propofol on hyperpolarization-activated cyclic nucleotide-gated (HCN1) ion channels. Remarkably, studies have shown that propofol can restore normal function to certain mutant HCN1 channels that are associated with severe, drug-resistant epilepsy syndromes.[86] This discovery opens the door to repurposing propofol at sub-anesthetic doses for these specific genetic epilepsies or, more likely, using its structure as a template to design novel, highly selective HCN1-modulating drugs. This marks a significant conceptual leap from using propofol for general CNS depression to using it to correct a specific molecular pathology.
• Treatment-Resistant Depression: The psychoactive effects of propofol have led to investigations into its potential as a rapid-acting antidepressant for patients with treatment-resistant depression, an area of active research.[9]
• Neuroprotection: Its established ability to decrease cerebral metabolism and potentially reduce oxidative damage continues to make it an agent of interest for neuroprotection in the setting of acute brain injury, though definitive clinical outcome benefits are still being studied.[3]

Conclusion

Propofol is an indispensable agent in the armamentarium of modern anesthesia and critical care. Its introduction over three decades ago was a landmark achievement in pharmaceutical science, providing clinicians with a tool that offered unprecedented control over the induction of and emergence from anesthesia. The resulting benefits—particularly the facilitation of ambulatory surgery and the improvement of the patient recovery experience—have been profound and far-reaching.

This profound clinical utility, however, is inextricably linked to a profile of significant risks. The narrow therapeutic index of propofol demands that its administration be restricted to highly skilled providers who are capable of managing its most severe cardiorespiratory complications. The ever-present danger of microbial contamination from its lipid emulsion vehicle requires unwavering adherence to strict aseptic protocols. The potential for abuse and diversion necessitates the regulatory controls of a scheduled substance. Finally, the specter of Propofol Infusion Syndrome, though rare, serves as a stark reminder of the drug's potential for catastrophic metabolic toxicity in vulnerable, critically ill patients, requiring constant vigilance and a deep understanding of its complex pathophysiology.

The future of propofol and its successors lies in a continued effort to enhance this delicate benefit-to-risk ratio. This will be achieved through the development of safer derivatives like ciprofol, which aim to refine the molecule's properties; the creation of more precise, feedback-controlled delivery systems that personalize dosing; and the exciting exploration of its specific molecular actions for novel, targeted therapies in fields like neurology. The legacy of propofol is one of transformation, and it will continue to evolve, pushing the boundaries of both anesthesia and neuroscience. Ultimately, harnessing the full potential of this powerful molecule while ensuring the highest standards of patient safety will depend on the continued commitment of clinicians and researchers to education, innovation, and vigilant clinical practice.

Works cited

1. Propofol's History in Medicine - Washington Anesthesia Partners, accessed July 16, 2025, https://www.anesthesiaserviceswa.com/propofols-history-in-medicine/
2. Clinical Pharmacokinetics and Pharmacodynamics of Propofol - PMC - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6267518/
3. Propofol - StatPearls - NCBI Bookshelf, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK430884/
4. Propofol: Essential Use in Modern Anesthesia - Farbe Firma, accessed July 16, 2025, https://www.farbefirma.org/post/propofol-essential-use-in-modern-anesthesia
5. Propofol: Understanding Its Role in Modern Anesthetic Practice - ResearchGate, accessed July 16, 2025, https://www.researchgate.net/publication/383623351_Propofol_Understanding_Its_Role_in_Modern_Anesthetic_Practice
6. Comprehensive Review of Propofol: Indications, Mechanisms, Adverse Effects, and Management Strategies in Anesthesia Practice | Request PDF - ResearchGate, accessed July 16, 2025, https://www.researchgate.net/publication/380153187_Comprehensive_Review_of_Propofol_Indications_Mechanisms_Adverse_Effects_and_Management_Strategies_in_Anesthesia_Practice
7. The Discovery and Development of Propofol Anesthesia: The 2018 Lasker-DeBakey Clinical Medical Research Award - ResearchGate, accessed July 16, 2025, https://www.researchgate.net/publication/327614605_The_Discovery_and_Development_of_Propofol_Anesthesia_The_2018_Lasker-DeBakey_Clinical_Medical_Research_Award
8. Propofol (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 16, 2025, https://www.mayoclinic.org/drugs-supplements/propofol-intravenous-route/description/drg-20488192
9. Propofol - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Propofol
10. Propofol: A Dangerous Kind of Rest - UChicago Medicine, accessed July 16, 2025, https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/propofol-a-dangerous-kind-of-rest
11. Propofol An Overview of Its Risks and Benefits. | Request PDF - ResearchGate, accessed July 16, 2025, https://www.researchgate.net/publication/253337727_Propofol_An_Overview_of_Its_Risks_and_Benefits
12. PROPOFOL (Trade Name: Diprivan®) - DEA Diversion Control Division, accessed July 16, 2025, https://www.deadiversion.usdoj.gov/drug_chem_info/propofol.pdf
13. ​Statement on Safe Use of Propofol, accessed July 16, 2025, https://www.asahq.org/standards-and-practice-parameters/statement-on-safe-use-of-propofol
14. DIPRIVAN (propofol) injectable emulsion, USP - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019627s066lbl.pdf?ref=linkstock
15. Propofol infusion syndrome - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Propofol_infusion_syndrome
16. Historical development of modern anesthesia - PubMed, accessed July 16, 2025, https://pubmed.ncbi.nlm.nih.gov/22583009/
17. Medical Milestones: Discovery of Anesthesia & Timeline - UMHS, accessed July 16, 2025, https://www.umhs-sk.org/blog/medical-milestones-discovery-anesthesia-timeline
18. Celebrating 30 Years of Diprivan : How Propofol Transformed the Practice of Anesthesia, accessed July 16, 2025, https://www.diprivan-us.com/Diprivan-SR+PI-11-4-2019.pdf
19. Veterinarian honored for propofol discovery | American Veterinary Medical Association, accessed July 16, 2025, https://www.avma.org/javma-news/2018-11-01/veterinarian-honored-propofol-discovery
20. Discovery and development of propofol, a widely used anesthetic - Lasker Foundation, accessed July 16, 2025, https://laskerfoundation.org/winners/discovery-and-development-of-propofol-a-widely-used-anesthetic/
21. Propofol | C12H18O | CID 4943 - PubChem, accessed July 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Propofol
22. Propofol - Deranged Physiology, accessed July 16, 2025, https://derangedphysiology.com/main/cicm-primary-exam/nervous-system/Chapter-211/propofol
23. How scientists developed the most popular anesthetic used today, without totally knowing how it works - Massive Science, accessed July 16, 2025, https://massivesci.com/articles/anesthesia-medicine-propofol-history-mechanism-drugs/
24. Application of different infusion methods of propofol in intravenous anesthesia: a narrative review - Digestive Medicine Research, accessed July 16, 2025, https://dmr.amegroups.org/article/view/7706/html
25. Propofol | C12H18O | CID 4943 - PubChem, accessed July 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/2078-54-8
26. Propofol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 16, 2025, https://go.drugbank.com/drugs/DB00818
27. CAS Number 2078-54-8 | 2,6-Diisopropylphenol - Spectrum Chemical, accessed July 16, 2025, https://www.spectrumchemical.com/cas/2078-54-8
28. Propofol EP Reference Standard CAS 2078-54-8 Sigma Aldrich, accessed July 16, 2025, https://www.sigmaaldrich.com/US/en/product/sial/y0000016
29. 2,6-Diisopropylphenol 2078-54-8 | Tokyo Chemical Industry Co., Ltd.(APAC), accessed July 16, 2025, https://www.tcichemicals.com/OP/en/p/D0617
30. Propofol | 2078-54-8 - ChemicalBook, accessed July 16, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4101882.htm
31. Propofol: Current Updates, Challenges, and Strategies for Improved ..., accessed July 16, 2025, https://pubs.acs.org/doi/10.1021/acsptsci.4c00745
32. Propofol: therapeutic indications and side-effects - PubMed, accessed July 16, 2025, https://pubmed.ncbi.nlm.nih.gov/15579060/
33. PROPROFOL (CIVICA®) (propofol injectable emulsion) Warnings and Precautions | Pfizer Medical - US, accessed July 16, 2025, https://www.pfizermedical.com/propofol-civica/warnings
34. What are contraindications of using propofol? | ClinicalKeyAI - Elsevier, accessed July 16, 2025, https://www.elsevier.com/resources/clinicalkey-ai/what-are-contraindications-of-using-propofol-35fc
35. propofol injectable emulsion (contains edetate disodium) Dosage and Administration | Pfizer Medical Information - US, accessed July 16, 2025, https://www.pfizermedicalinformation.com/propofol/dosage-admin
36. Propofol: Package Insert / Prescribing Information - Drugs.com, accessed July 16, 2025, https://www.drugs.com/pro/propofol.html
37. Propofol: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed July 16, 2025, https://www.drugs.com/propofol.html
38. Propofol Infusion Syndrome in Adults: A Clinical Update - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4410753/
39. Propofol Monograph for Professionals - Drugs.com, accessed July 16, 2025, https://www.drugs.com/monograph/propofol.html
40. DIPRIVAN (propofol) injectable emulsion, USP - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019627s066lbl.pdf
41. propofol - PharmGKB, accessed July 16, 2025, https://www.pharmgkb.org/chemical/PA451141
42. PROPROFOL (CIVICA®) (propofol injectable emulsion) Indications and Usage | Pfizer Medical Information - US, accessed July 16, 2025, https://www.pfizermedicalinformation.com/propofol-civica/indications-usage
43. DIPRIVAN® (propofol injectable emulsion), for intravenous use - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019627s069lbl.pdf
44. Propofol Injection: MedlinePlus Drug Information, accessed July 16, 2025, https://medlineplus.gov/druginfo/meds/a625006.html
45. Propofol Dosing Guidelines, accessed July 16, 2025, https://web.stanford.edu/~sshafer/LECTURES.DIR/Notes/Propofol%20Guide.doc
46. Diprivan (propofol) dosing, indications, interactions, adverse effects, and more, accessed July 16, 2025, https://reference.medscape.com/drug/diprivan-propofol-343100
47. PROPROFOL (CIVICA®) (propofol injectable emulsion) Drug Interactions | Pfizer Medical - US, accessed July 16, 2025, https://www.pfizermedical.com/propofol-civica/drug-interactions
48. PROPOFOL (Diprivan) - London Health Sciences Centre, accessed July 16, 2025, https://www.lhsc.on.ca/critical-care-trauma-centre/propofol-diprivan
49. Propofol as an Intravenous Agent in General Anesthesia and Conscious Sedation - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2167960/
50. Propofol Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 16, 2025, https://www.drugs.com/dosage/propofol.html
51. Propofol Use in the Elderly Population: Prevalence of Overdose and Association With 30-Day Mortality - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5864105/
52. The Impact of Age on Propofol Requirement for Inducing Loss of Consciousness in Elderly Surgical Patients - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8996377/
53. Propofol - WikEM, accessed July 16, 2025, https://wikem.org/wiki/Propofol
54. pmc.ncbi.nlm.nih.gov, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3526928/#:~:text=Propofol%20is%20approved%20by%20the,18%20mg%2F%20kg%2Fhour.
55. Propofol - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 16, 2025, https://www.pediatriconcall.com/drugs/propofol/904
56. highlights of prescribing information - Pfizer, accessed July 16, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=15589
57. What is the appropriate dosing of propofol for procedural sedation? - Dr.Oracle AI, accessed July 16, 2025, https://www.droracle.ai/articles/22620/procedural-sedation-with-propofol-dosing
58. Pharmacology - Agents for Induction and Maintenance of Anesthesia - AnesthesiologyQR: A Quick Reference for medical students learning anesthesiology at University of Toronto, accessed July 16, 2025, http://pie.med.utoronto.ca/anesthesiaqr/AnesthesiaQR_content/AnesthesiaQR_Pharmacology_Anesthetic_agents.html
59. Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2801588/
60. Propofol (marketed as Diprivan and as generic products) Information - FDA, accessed July 16, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/propofol-marketed-diprivan-and-generic-products-information
61. Propofol Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 16, 2025, https://www.drugs.com/sfx/propofol-side-effects.html
62. Propofol - WikiAnesthesia, accessed July 16, 2025, https://wikianesthesia.org/wiki/Propofol
63. Propofol Toxicity - StatPearls - NCBI Bookshelf, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK541077/
64. PROPROFOL (CIVICA®) (propofol injectable emulsion) Contraindications | Pfizer Medical Information - US, accessed July 16, 2025, https://www.pfizermedicalinformation.com/propofol-civica/contradictions
65. Propofol Interactions Checker - Drugs.com, accessed July 16, 2025, https://www.drugs.com/drug-interactions/propofol.html
66. Propoven Interactions Checker - Drugs.com, accessed July 16, 2025, https://www.drugs.com/drug-interactions/propofol,propoven.html
67. Propofol injection - Cleveland Clinic, accessed July 16, 2025, https://my.clevelandclinic.org/health/drugs/19862-propofol-injection
68. Schedules of Controlled Substances: Placement of Propofol Into Schedule IV - Federal Register, accessed July 16, 2025, https://www.federalregister.gov/documents/2010/10/27/2010-27193/schedules-of-controlled-substances-placement-of-propofol-into-schedule-iv
69. Propofol infusion syndrome | BJA Education - Oxford Academic, accessed July 16, 2025, https://academic.oup.com/bjaed/article/13/6/200/246704
70. Propofol infusion syndrome - Medic's Corner, accessed July 16, 2025, http://www.jvsmedicscorner.com/ICU-Miscellaneous_files/Propofol%20Infusion%20syndrome%20Review.pdf
71. Propofol Infusion Syndrome: Topic Review, accessed July 16, 2025, http://www.scielo.org.co/scielo.php?pid=S2011-08392021000200018&script=sci_abstract
72. Successful treatment of propofol-related infusion syndrome in critically ill patient receiving low-dose propofol infusion: a case report, accessed July 16, 2025, https://www.accjournal.org/journal/view.php?number=1325
73. Propofol infusion syndrome: update of clinical manifestation and pathophysiology | Familias GA, accessed July 16, 2025, http://familiasga.com/wp-content/uploads/2019/07/Propofol-infusion-syndrome-update-of-clinical-manifestation-and-pathophysiology.pdf
74. Propofol Infusion Syndrome: A Case Report | Rewa | Journal of Medical Cases, accessed July 16, 2025, https://www.journalmc.org/index.php/JMC/article/view/1269
75. Propofol-Related Infusion Syndrome (PRIS), accessed July 16, 2025, https://cumming.ucalgary.ca/sites/default/files/teams/127/pearl-ofthe-week/Propofol-related%20infusion%20syndrome%20May%202019.pdf
76. Propofol Related Infusion Syndrome (PRIS) - First10EM, accessed July 16, 2025, https://first10em.com/propofol-related-infusion-syndrome-pris/
77. Propofol-Related Infusion Syndrome: A Clinical Review - PMC - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9671386/
78. Propofol-Related Infusion Syndrome - University of Virginia School of Medicine, accessed July 16, 2025, https://med.virginia.edu/ginutrition/wp-content/uploads/sites/199/2014/06/MikeArticle.pdf
79. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome - PubMed, accessed July 16, 2025, https://pubmed.ncbi.nlm.nih.gov/12904852/
80. (PDF) Propofol-Related Infusion Syndrome: A Clinical Review - ResearchGate, accessed July 16, 2025, https://www.researchgate.net/publication/364439139_Propofol-Related_Infusion_Syndrome_A_Clinical_Review
81. Propofol Infusion Syndrome, accessed July 16, 2025, https://resources.wfsahq.org/wp-content/uploads/4c629772d6178d2ea9e22f3a65ff8aaf-atow-435-00.pdf
82. Propofol Infusion Syndrome in Adults: A Clinical Update - PMC, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410753/
83. Propofol use for sedation during endoscopy in adults: A Canadian Association of Gastroenterology position statement - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2660799/
84. Recent advances in using propofol by non-anesthesiologists - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2998802/
85. Propofol Completed Phase 3 Trials for Sedation or Anesthesia Treatment | DrugBank Online, accessed July 16, 2025, https://go.drugbank.com/drugs/DB00818/clinical_trials?conditions=DBCOND0114093&phase=3&purpose=treatment&status=completed
86. A New Use for Propofol in Treating Epilepsy? | Graduate School of Medical Sciences, accessed July 16, 2025, https://gradschool.weill.cornell.edu/news/new-use-propofol-treating-epilepsy
87. Unlocking Propofol's Potential in Epilepsy Treatment - InventUM - University of Miami, accessed July 16, 2025, https://news.med.miami.edu/unlocking-propofols-potential-in-epilepsy-treatment/